Ebola (Ebola Hemorrhagic Fever)
Ebola (Ebola Hemorrhagic Fever)
Experimental Ebola Vaccines
- As of October 2014 there are no FDA approved vaccines for Ebolavirus.
- There are several experimental Ebolavirus vaccines that have been in development for more than a decade and are currently being tested to respond to the 2014 outbreak of Zaire ebolavirus.
- Clinical trails for a few experimental vaccines are being conducted in the U.S., United Kingdom and Africa.
- Preliminary data on experimental vaccines in clinical trials is estimated to be available late 2015 and may be fast tracked by FDA for widespread use.
Experimental Ebola Drug
- As of October 2014 there are no FDA approved drugs for the treatment of Ebola.
- ZMapp, an experimental therapeutic drug developed by Mapp Biopharmaceutical Inc., is designed to treat people infected with Ebola virus and is not designed to prevent infection.
- ZMapp has been shown to prevent Ebola infection in monkeys and was the experimental drug given to two U.S. missionaries working in Liberia, who contracted Ebolavirus in 2014 and survived.
- According to the CDC, “It is too early to know whether ZMapp is effective, since it is still in an experimental stage and has not yet been tested in humans for safety or effectiveness.”
Food & Drug Administration (FDA)
Centers for Disease Control (CDC)
National Institutes of Health (NIH) and Affiliates
World Health Organization (WHO)
Vaccine Reaction Symptoms & Ingredients
Our Ask 8, If You Vaccinate webpage contains vaccine reaction symptoms and more. Calculate vaccine ingredients for potential toxic exposures & print a vaccination plan with the Vaccine Ingredients Calculator.
Search for Vaccine Reactions
NVIC hosts MedAlerts, a powerful VAERS database search engine. MedAlerts examines symptoms, reactions, vaccines, dates, places, and more.
Reporting a Vaccine Reaction
Since 1982, the NVIC has operated a Vaccine Reaction Registry, which has served as a watchdog on VAERS. Reporting vaccine reactions to VAERS is the law. If your doctor will not report a reaction, you have the right to report a suspected vaccine reaction to VAERS.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Diphtheria and the Diphtheria vaccine by reading all sections in the Table of Contents , which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
Learn More About Ebola and Ebola Vaccine
What is Ebola?
Ebola is a very contagious disease in non-human primates (monkeys, gorillas, and chimpanzees) and humans with a high mortality rate. The natural reservoir for the virus is thought to be a fruit bat living in Africa.1
Ebolavirus and Marburgvirus belong to the family Filoviridae and cause suppression of innate and adaptive immune responses that lead to a syndrome resembling septic shock.2 There are five species of Ebolavirus (Zaire, Sudan, Ivory Coast, Bundibugyo and Reston) and the 2014 Ebola outbreak is being caused Zaire ebolavirus.3
Symptoms start with a fever, headache, muscle and stomach pain, diarrhea, vomiting, skin bruising and, in severe cases, can progress to septic shock and liver, kidney and other body organ failure with bleeding from the nose, mouth and gastrointestinal tract.
Is Ebola Communicable?
Yes. Ebolavirus is spread through inhalation, ingestion and or passage through breaks in the skin when an uninfected person comes in contact with the body fluids (blood, saliva, nasal secretions, stool, vomit, breastmilk, semen, urine, tears) of an infected person or the cadaver of a person who died from Ebola.4 Ebola is also thought to be spread when a person comes in contact with bandages, clothes or other objects that have been contaminated with body fluids, especially blood, of an infected person.5 6
Depending upon the body fluid, Ebolavirus has been detected in body fluids from 6 to 40 days after disease onset, including during the convalescent stage.7
After coming in contact with someone infected with Ebola, the incubation period from initial exposure to onset of acute disease symptoms is between 2 and 21 days with the average being 6 to 10 days.8
There is some evidence that Ebola may be spread when an infected person coughs or sneezes into the air but there is disagreement among scientists and public health officials about whether or not airborne transmission does
There is also disagreement about whether or not an infected person, who is not exhibiting a fever or other acute signs of illness, can still transmit infection to others.14 15
Those who recover from Ebola virus infection may develop antibodies lasting 10 years or longer, but it is not known if they can become immune for life or if they are susceptible to infection from different strains of Ebola virus.16
History of Ebola
The first Filovirus (Marburg) was identified in 1967 when about 30 laboratory workers in Germany and Yugoslavia developed hemorrhagic fever and seven died. The workers had handled kidney tissues from infected African green monkeys imported from Uganda when they were preparing primary cell cultures for polio vaccine production.17 18
Before a large outbreak in Guinea, Liberia and Sierra Leone in 2014, Ebola outbreaks during the past two decades were sporadic and primarily confined to Africa.19
Can Ebola Cause Injury and Death?
Yes. Historically, between 25 and 90% of Ebola cases have ended in death and the Africa-based outbreak that began in Guinea, Liberia and Sierra Leone in 2014 has been averaging a 40 to 70% case fatality rate.20 Individuals who recover from Ebola can experience long-term complications like joint and vision problems.21
In non-fatal cases, health improvement is seen between days 6 and 11 after onset of symptoms. In fatal cases, death usually occurs within 6 to 16 days.22
Ebola Prevention and Treatment Options
As of October 2014 there are no FDA approved vaccines for the prevention of Ebolavirus,23 though several are under development.
Currently there are no FDA approved drugs for the treatment of Ebola and symptoms are treated as they develop. Treatment with intravenous fluids, maintaining oxygen and blood pressure levels and treatment of secondary infections when they occur “can significantly improve the chances of survival” when used early.24
Mapp Biopharmaceutical Inc. has developed an experimental therapeutic drug, ZMapp, to treat infected individuals. According to the CDC “ZMapp is a combination of three monoclonal antibodies manufactured in tobacco plants. Monoclonal antibodies bind certain virus proteins and neutralize the virus, decreasing the amount of the virus in the body that the patient's immune system has to fight.”
ZMapp has been shown to prevent Ebola infection in monkeys and was the experimental drug given to two U.S. missionaries working in Liberia, who contracted Ebolavirus in 2014. These missionaries survived after being given ZMapp,25 26 however, the CDC has stated that this drug has not been fully tested in humans for safety or effectiveness.27
What are Experimental Ebola Vaccines?
There are several experimental Ebolavirus vaccines that have been in development for more than a decade and are currently being tested to respond to the 2014 outbreak of Zaire ebolavirus. One of the Ebola vaccines has been developed by the U.S. government and one by the Canadian government.28 There is another Ebolavirus vaccine being co-developed by a U.S. company and the Centers for Disease Control.29
The National Institute of Allergy and Infectious Diseases (NIAID) with GlaxoSmithKline (GSK) has developed a genetically engineered chimpanzee-derived adenovirus vectored Ebola vaccine with two inserted Ebolavirus genes (cAd3-ZEBOV).30 31 A U.S. clinical trial with 20 participants32 and a UK clinical trial with 60 participants are being conducted followed by clinical trials in two African countries each with 40 participants.33
The Public Health Agency of Canada has developed a genetically engineered Ebola vaccine (rVSV-ZEBOV) and the license for the vaccine is held by NewLink Genetics, a U.S. company. The Canadian Ebola vaccine uses an attenuated vesicular stomatitis virus, a pathogen that infects livestock (cattle, horses, deer, pigs) with one of its genes replaced by an Ebolavirus gene.34 35]
GeoVax Labs, Inc. is collaborating with the Centers for Disease Control to develop and test two experimental Ebola vaccines (GOVX-E301 and GOVX-E302) which are recombinant modified vaccinia Ankara (MVA) vaccines that will produce virus-like particles (VLPs) displaying the Ebola virus glycoprotein.36
What is Known about Experimental Ebola Vaccines?
As of October 2014 there are no FDA approved Ebola vaccines. Ebola vaccines in use are experimental and their safety and effectiveness are unknown.37
Preliminary data on the NIAID/GSK vaccine is estimated by December 2015 and the vaccine may be fast tracked by FDA into widespread use. A placebo controlled U.S. clinical trial of the VSV Ebola vaccine is scheduled to be completed in October 2015.38
NVIC's Ebola Commentaries and Video Collection
NVIC Ebola Video Playlist
View the collection of video resources within the player below for more information on ebola and the ebola vaccine.
To view the entire video collection, click the hamburger menu in the upper left corner of the video player above. This will expand a full list of videos. You may also open the video player in full screen mode for optimal display.
NVIC Statements & Commentaries
Will There Be An Ebola Outbreak in America? – Oct. 15, 2014
Additional Federal Agency Ebola Resource Information
Centers for Disease Control (CDC)
Food and Drug Administration (FDA)
National Institutes of Health (NIH)
World Health Organization (WHO)
World Health Organization (WHO). Ebola Virus Disease
. WHO Fact Sheet
Centers for Disease Control. CDC Case Definition for Ebola Virus Disease (EVD), Low Risk Exposures (“A low risk exposure includes any of the following: Household contact with an EVD patient; other close contact with EVD patients in health care facilities or community settings. Close contact is defined as (a) being within approximate 3 feet of an EVD patient or within the patient’s room or care area for a prolonged period of time while not wearing recommended personal protective equipment.”
) CDC Website
Sept. 5, 2014.